CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $28.22M, lower than 95% of all stocks globally
- FinancialsHigh structural barrier to entry
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
304.73MUSDvs all stocks (USD)
Revenue (TTM)
28.22MUSDvs all stocks (USD)
Profit Margin
-266.88%vs Biotechnology peers
Beta
2.86xvs all stocks
52-Week Change
-14.92%vs all stocks
Market Capitalization
304.73MUSDvs all stocks (USD)
Enterprise Value
178.35MUSDvs all stocks (USD)
Forward P/E
-4.62xvs Biotechnology peers
Price to Sales (TTM)
10.55xvs Biotechnology peers
Enterprise to Revenue
6.32xvs Biotechnology peers
Enterprise to EBITDA
-2.29xvs Biotechnology peers
Profit Margin
-266.88%vs Biotechnology peers
Operating Margin
-660.33%vs Biotechnology peers
Return on Assets (TTM)
-21.00%vs Biotechnology peers
Revenue (TTM)
28.22MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.4370USDUpdated Jul 18, 2026Quarterly Revenue Growth
-45.10%vs Biotechnology peers
Gross Profit (TTM)
-53.88MUSDvs all stocks (USD)
EBITDA (TTM)
-78.02MUSDvs all stocks (USD)
Net Income (TTM)
-75.32MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-45.11%vs Biotechnology peers
Operating Cash Flow (TTM)
-87.40MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-36.93MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
30.91MUSDFY2025 · Dec 31, 2025Operating Income
-82.11MUSDvs all stocks (USD)
Pre-tax Income
-74.28MUSDFY2025 · Dec 31, 2025Net Income
-74.28MUSDFY2025 · Dec 31, 2025EBIT
-82.11MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-74.49MUSDFY2025 · Dec 31, 2025Research & Development
85.47MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
27.55MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
8.74MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-74.28MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-95.15MUSDFY2025 · Dec 31, 2025Free Cash Flow
-95.20MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
84.13MUSDFY2025 · Dec 31, 2025Income Tax Paid
9.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-74.28MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.33MUSDFY2025 · Dec 31, 2025Stock-based Compensation
10.40MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.57MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
481.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-37.65MUSDFY2025 · Dec 31, 2025Capital Expenditures
-50.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-131.25MUSDFY2025 · Dec 31, 2025Sale of Investments
243.34MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
112.04MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
540.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
58.71MSharesUpdated Jul 18, 2026Float Shares
27.41MSharesUpdated Jul 18, 2026Shares Short
1.60MSharesUpdated Jul 18, 2026Short Ratio
7.17daysvs all stocks
Short % of Shares Outstanding
4.98%vs all stocks
% Held by Insiders
14.30%vs all stocks
% Held by Institutions
76.58%vs all stocks
Total Cash (MRQ)
183.63MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.13USDUpdated Jul 18, 2026Total Debt (MRQ)
41.99MUSDvs all stocks (USD)
Current Ratio (MRQ)
2.92xvs Biotechnology peers
Book Value per Share (MRQ)
-1.30USDUpdated Jul 18, 2026Total Assets
198.10MUSDvs all stocks (USD)
Total Current Assets
163.24MUSDFY2025 · Dec 31, 2025Total Liabilities
306.60MUSDFY2025 · Dec 31, 2025Total Non-current Assets
34.87MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
246.87MUSDFY2025 · Dec 31, 2025Total Current Liabilities
59.74MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
80.88MUSDFY2025 · Dec 31, 2025Other Short-term Investments
78.02MUSDFY2025 · Dec 31, 2025Accounts Payable
4.27MUSDFY2025 · Dec 31, 2025Short-term Debt
923.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
43.19MUSDFY2025 · Dec 31, 2025Other Current Liabilities
400.00KUSDFY2025 · Dec 31, 2025Long-term Debt
40.35MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
556.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-632.47MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-108.50MUSDvs all stocks (USD)
52-Week Low
3.27USDUpdated Jul 18, 202652-Week High
6.95USDUpdated Jul 18, 202652-Week Change
-14.92%vs all stocks
Beta
2.86xvs all stocks
50-Day MA
4.42USDUpdated Jul 18, 2026200-Day MA
4.85USDUpdated Jul 18, 2026Avg 10-Day Volume
499.86KSharesUpdated Jul 18, 2026Avg 30-Day Volume
321.01KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-1.17USDUpdated Jul 18, 2026Other Income / Expense
-921.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 52.79
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $28.22M, lower than 95% of all stocks globallySignificant
Revenue (USD): 28,224,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Essex Bio-Technology Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hikal Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tanvex Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
JBM
Tier 1ProductionApproval-Gated PipelineRuleFlow
908 Devices Inc.
Tier 1ProductionApproval-Gated PipelineRule
Il Dong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Immuneering Corporation
Tier 1ProductionApproval-Gated PipelineRule
AP Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Solara Active Pharma Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Huangshan Capsule Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
The Baldwin Group, Inc.
1 interpretationOperating Income Growing With Multi-Year Revenue Growth
Viant Technology Inc.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
ServiceNow, Inc.
2 interpretationsOperating Income Growing With Multi-Year Revenue GrowthUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated